11th March 2021

MarketsandMarkets Bioproduction CRYSTAL BALL EVENT

High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MNM’s Crystal Ball event

The end product sales in bioproduction market are expected to be grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and biobetters, plasma therapy as well as others.

A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc can benefit from this unprecedented growth over the next 5 years.

This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space

WHAT TO EXPECT
Key Highlights
  • Continuous biomanufacturing is expected to double in the next 5 years, garnering larger share from conventional batch processing.
  • Alternative and Novel downstream bioprocessing techniques generate a significant share of over $16 billion growth overall.
  • Increasing demand for major end products led by monoclonal antibodies, vaccines, biosimilars, biobetters, plasma therapy, cell & gene therapy and human microbiome therapeutics, are growing at 3 times the rate of conventional therapeutics.
Crystal Ball: Through the Speakers Perspective
  • How can Cell therapy market expand faster in non-oncology indications & out of US and how can this transition be expedited?
  • Which technologies can result in the improvement of production yields and optimize supply chain of COVID-19 vaccine?
  • Why is the mRNA vaccine approval so pivotal for the future of disease therapeutics?
  • What could be characteristics for an ideal biotech innovator &CROs/CMOs corporation for accelerating development and commercialization of cell-based therapeutics?
CONFERENCE AGENDA
CONFERENCE SPEAKERS
Past Speakers
Devyn Smith

Devyn Smith

Chief Operating Officer
Sigilon Therapeutics

Devyn Smith

Chief Operating Officer
Sigilon Therapeutics
Mahendra Rao

Mahendra Rao

Chief Executive Officer
panCella

Mahendra Rao

Chief Executive Officer
panCella
Sarindr Bhumiratana

Sarindr Bhumiratana

Chief Scientific Officer
Epibone

Sarindr Bhumiratana

Chief Scientific Officer
Epibone
Rajesh Desikan

Rajesh Desikan

Vice President & Head, US Marketing, Oncology & Immunology Biosimilars
Fresenius Kabi, USA

Rajesh Desikan

Vice President & Head, US Marketing, Oncology & Immunology Biosimilars
Fresenius Kabi, USA
Sarfaraz K. Niazi

Sarfaraz K. Niazi

Professor Adjunct of Biopharmaceutical Sciences
University of Illinois at Chicago

Sarfaraz K. Niazi

Professor Adjunct of Biopharmaceutical Sciences
University of Illinois at Chicago
Berit Lindholm

Berit Lindholm

Chief Executive Officer
Bluefish Pharmaceuticals

Berit Lindholm

Chief Executive Officer
Bluefish Pharmaceuticals
Jim Marshall

Jim Marshall

Devens Biologics Head of Supply Chain
Bristol-Myers Squibb

Jim Marshall

Devens Biologics Head of Supply Chain
Bristol-Myers Squibb
Luiz Barberini

Luiz Barberini

Operations Manager, External Manufacturing Latin America Head
Bayer

Luiz Barberini

Operations Manager, External Manufacturing Latin America Head
Bayer
PAST EVENT GALLERY